Letter to the Editor

Split Viewer

Blood Res 2016; 51(2):

Published online June 23, 2016

https://doi.org/10.5045/br.2016.51.2.137

© The Korean Society of Hematology

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab

Andrea Tendas, Pasquale Niscola*, Laura Scaramucci, Luca Cupelli, Alessio Pio Perrotti, and Paolo de Fabritiis

Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.

Correspondence to : Pasquale Niscola. Hematology Unit, San'Eugenio Hospital, Piazzale dell'Umanesimo 10, Rome 00144, Italy. pniscola@gmail.com

Received: June 11, 2015; Revised: August 8, 2015; Accepted: September 1, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fig. 1.

Treatments and their effects on the patient's hemoglobin (Hb) level and reticulocyte count.

Abbreviations: CyA, oral cyclosporine A (mg/day); RTX, rituximab; PDN 1, oral prednisone 1 mg/m2/day; AZT, oral azathioprine.


Table. 1.

Table 1 Laboratory findings at the PRCA diagnosis.

Abbreviations: WBC, white blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenases; PT, prothrombin time; aPTT, activated partial thromboplastin time.


  1. Sawada, K, Fujishima, N, Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol, 2008;142;505-514.
    Pubmed
  2. D'Arena, G, Vigliotti, ML, Dell'Olio, M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol, 2009;82;235-239.
    Pubmed
  3. Scaramucci, L, Niscola, P, Ales, M, et al. Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol, 2008;88;343-344.
    Pubmed
  4. Gupta, RK, Ezeonyeji, AN, Thomas, AS, Scully, MA, Ehrenstein, MR, Isenberg, DA. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus, 2011;20;1547-1550.
    Pubmed
  5. Jung, SH, Ahn, JS, Yang, DH, et al. Successful treatment of pure red cell aplasia with rituximab in patients after abo-compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol, 2012;5;110-113.
    Pubmed

Article

Letter to the Editor

Blood Res 2016; 51(2): 137-138

Published online June 23, 2016 https://doi.org/10.5045/br.2016.51.2.137

Copyright © The Korean Society of Hematology.

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab

Andrea Tendas, Pasquale Niscola*, Laura Scaramucci, Luca Cupelli, Alessio Pio Perrotti, and Paolo de Fabritiis

Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.

Correspondence to: Pasquale Niscola. Hematology Unit, San'Eugenio Hospital, Piazzale dell'Umanesimo 10, Rome 00144, Italy. pniscola@gmail.com

Received: June 11, 2015; Revised: August 8, 2015; Accepted: September 1, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Fig 1.

    Figure 1.

    Treatments and their effects on the patient's hemoglobin (Hb) level and reticulocyte count.

    Abbreviations: CyA, oral cyclosporine A (mg/day); RTX, rituximab; PDN 1, oral prednisone 1 mg/m2/day; AZT, oral azathioprine.

    Blood Research 2016; 51: 137-138https://doi.org/10.5045/br.2016.51.2.137

    Table 1 . Laboratory findings at the PRCA diagnosis..

    Abbreviations: WBC, white blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenases; PT, prothrombin time; aPTT, activated partial thromboplastin time..


    References

    1. Sawada, K, Fujishima, N, Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol, 2008;142;505-514.
      Pubmed
    2. D'Arena, G, Vigliotti, ML, Dell'Olio, M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol, 2009;82;235-239.
      Pubmed
    3. Scaramucci, L, Niscola, P, Ales, M, et al. Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol, 2008;88;343-344.
      Pubmed
    4. Gupta, RK, Ezeonyeji, AN, Thomas, AS, Scully, MA, Ehrenstein, MR, Isenberg, DA. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus, 2011;20;1547-1550.
      Pubmed
    5. Jung, SH, Ahn, JS, Yang, DH, et al. Successful treatment of pure red cell aplasia with rituximab in patients after abo-compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol, 2012;5;110-113.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download